PMC:7200337 / 94716-96183
Annnotations
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32505227-32155444-46575426 | 139-143 | 32155444 | denotes | 2020 |
T4350 | 139-143 | 32155444 | denotes | 2020 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T736 | 261-266 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T737 | 590-598 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T738 | 767-772 | Body_part | denotes | serum | http://purl.org/sig/ont/fma/fma63083 |
T739 | 937-945 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T740 | 994-1002 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T98 | 767-772 | Body_part | denotes | serum | http://purl.obolibrary.org/obo/UBERON_0001977 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T542 | 33-41 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T543 | 44-53 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T544 | 626-634 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T545 | 905-913 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T546 | 1011-1019 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T547 | 1084-1092 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T548 | 1207-1215 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T549 | 1288-1296 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T550 | 1406-1415 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T974 | 259-266 | http://purl.obolibrary.org/obo/CL_0000236 | denotes | B cells |
T975 | 807-809 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
T976 | 903-904 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T977 | 979-980 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T978 | 1175-1176 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T979 | 1241-1242 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T980 | 1243-1252 | http://purl.obolibrary.org/obo/CLO_0036932 | denotes | hybridoma |
T981 | 1263-1264 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T982 | 1326-1327 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T983 | 1440-1441 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T210 | 252-258 | http://purl.obolibrary.org/obo/GO_0007613 | denotes | memory |
T211 | 590-622 | http://purl.obolibrary.org/obo/GO_0097282 | denotes | antibody-mediated neutralization |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
3134 | 561-565 | Gene | denotes | ACE2 | Gene:59272 |
3135 | 681-685 | Gene | denotes | ACE2 | Gene:59272 |
3136 | 855-859 | Gene | denotes | ACE2 | Gene:59272 |
3137 | 1114-1118 | Gene | denotes | ACE2 | Gene:59272 |
3138 | 1389-1391 | Gene | denotes | to | Gene:6999 |
3139 | 1377-1379 | Gene | denotes | to | Gene:6999 |
3140 | 1070-1072 | Gene | denotes | to | Gene:6999 |
3141 | 804-806 | Gene | denotes | to | Gene:6999 |
3142 | 644-646 | Gene | denotes | to | Gene:6999 |
3143 | 317-319 | Gene | denotes | to | Gene:6999 |
3144 | 199-201 | Gene | denotes | to | Gene:6999 |
3145 | 0-8 | Species | denotes | Patients | Tax:9606 |
3146 | 626-636 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3147 | 789-797 | Species | denotes | patients | Tax:9606 |
3148 | 905-913 | Species | denotes | SARS-CoV | Tax:694009 |
3149 | 1011-1021 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3150 | 1084-1094 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3151 | 1207-1217 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3152 | 1288-1298 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
3153 | 1380-1388 | Species | denotes | patients | Tax:9606 |
3154 | 328-339 | Species | denotes | recombinant | Tax:575864 |
3155 | 82-86 | Chemical | denotes | nAbs | |
3156 | 215-219 | Chemical | denotes | nAbs | |
3157 | 1276-1279 | Chemical | denotes | nAb | |
3158 | 33-53 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
3159 | 1406-1415 | Disease | denotes | infection | MESH:D007239 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T545 | 0-185 | Sentence | denotes | Patients who have recovered from SARS-CoV-2 infection are one potential source of nAbs (Chen et al., 2020a, Ju et al., 2020, Walls et al., 2020, Wölfel et al., 2020, Yuan et al., 2020). |
T546 | 186-416 | Sentence | denotes | In an effort to obtain these nAbs, scientists sorted RBD-specific memory B cells and cloned their heavy and light variable regions to express recombinant forms of the corresponding antibodies (Chen et al., 2020a, Ju et al., 2020). |
T547 | 417-578 | Sentence | denotes | Four of the antibodies produced in these studies (31B5, 32D4, P2C-2F6, P2C-1F11) showed high neutralizing potential in vitro, and all inhibited ACE2-RBD binding. |
T548 | 579-698 | Sentence | denotes | Successful antibody-mediated neutralization of SARS-CoV-2 seemed to be dependent on the inhibition of ACE2/RBD binding. |
T549 | 699-893 | Sentence | denotes | However, Chen et al. showed that nearly all antibodies derived from serum of 26 recovered patients bound to S1 and RBD, with only three actually inhibiting ACE2/RBD binding (Chen et al., 2020a). |
T550 | 894-1131 | Sentence | denotes | Of note, a SARS-CoV-1-derived neutralizing antibody (47D11) (Wang et al., 2020a) and a single-chain antibody against SARS-CoV-2 (n3130) (Wu et al., 2020c) have also been shown to neutralize SARS-CoV-2 without inhibiting ACE2/RBD binding. |
T551 | 1132-1222 | Sentence | denotes | Thus, blocking this interaction may not be a prerequisite for an effective SARS-CoV-2 nAb. |
T552 | 1223-1467 | Sentence | denotes | The generation of a hybridoma producing a monoclonal nAb against SARS-CoV-2 provides the potential for a therapeutic Ab that can be directly administered to patients to block ongoing infection and potentially even as a prophylactic (Figure 6D). |